Skip to content

Epidaurus · Treatment Guide · Therapeutic Interventions

Going abroad for —

Stem Cell Transplant Quality

Evidence-based stem cell and bone marrow transplant for hematologic conditions

The country comparison

Which countries are best for stem cell transplant quality

The destinations ranked high→low under this lens — each with the reasoning behind its score, the cited evidence one click down, and its full report. The verdict is free; the report is the depth.

19 / 19 Countries ranked

Researched and assessed by the Epidaurus editorial pipeline against our published scale. A country below the rule is not yet assessed enough — never ranked last.

  1. 1 Germany DE 5.0/5 Good Germany meets or exceeds all Score 5 criteria, demonstrating world-leading stem cell transplant capabilities. The country operates one of Europe's densest JACIE-accredited networks with multiple centers performing >10... Full report
    The evidence behind this score 5 cited points
    • Ten German centers achieved JACIE accreditation in 2024; Germany operates one of Europe's most extensive networks of accredited stem cell transplant centers with 133 centers participating in the national DRST registry
    • Heidelberg University Hospital performs >300 transplants annually; University Hospital Freiburg performs >200/year; Germany ranks 2nd in Europe for allogeneic HCT activity at 422.8 procedures per 10 million inhabitants
    • 1-year overall survival of 71.1% at high-volume German centers for allogeneic AML; 5-year OS of 62.2% for autologous DLBCL; treatment-related mortality 9.5% (2013-2016 EBMT data)
    • DKMS maintains 13 million registered donors globally (8 million in Germany); ZKRD provides access to 44.7 million international donors; 9 of 10 German patients find a suitable donor within weeks
    • Comprehensive international patient programs at LMU Munich, Heidelberg, Freiburg, and Charité Berlin with multilingual support, telemedicine, and structured post-transplant follow-up; full spectrum of transplant modalities available including haploidentical and cord blood programs

    Read the full Germany report →

  2. 2 United States US 5.0/5 Good The United States operates an exceptional stem cell transplantation system meeting all Score 5 criteria. Multiple FACT/JACIE-accredited centers perform >100 annual transplants, with leading institutions achieving 1-ye... Full report
    The evidence behind this score 6 cited points
    • Multiple FACT/JACIE-accredited centers (City of Hope, Dana-Farber, Sarah Cannon's 9 programs, MUSC, University of Iowa, UC Davis, WRNMMC and others) with City of Hope performing most allogeneic transplants nationally and Dana-Farber performing ~500/year
    • Exceptional 1-year survival rates: Dana-Farber adult 80.6% actual vs 74.5% expected; pediatric 91.9% vs 85.9% expected; 5-year survival 86%, with only 12 of 172 centers (7%) achieving this performance level
    • Largest donor registry access: 9.4 million US donors and 246,500 cord blood units; each search provides 42+ million potential donors and 800,000 CBUs through 48 global cooperative registries
    • Comprehensive alternative donor programs: Fred Hutch >700 haploidentical and cord blood transplants; haplo-cord transplants showing 80.5% 3-year survival vs 67.8% haploidentical-only
    • Mandatory federal outcomes reporting via Stem Cell Therapeutic and Research Act (2005) with CIBMTR managing SCTOD database and transparent center-specific public data
    • Established international patient services: Mayo Clinic (130+ countries annually), Dana-Farber (remote consults, translated materials, housing coordination), Advanced Care at Home post-transplant support

    Read the full United States report →

  3. 3 Spain ES 5.0/5 Good Spain operates one of Europe's most advanced stem cell transplant systems with 11 JACIE-accredited centers (the highest national count globally in 2024), performing 3,717 procedures annually. The country demonstrates ... Full report
    The evidence behind this score 8 cited points
    • 11 Spanish centres achieved or renewed JACIE accreditation in 2024 — the highest global national count; named accredited centres include Hospital Clínic de Barcelona, Institut Català d'Oncologia, Hospital Universitario de Navarra, Hospital Clínico Universitario de Valencia
    • 3,717 HSCTs performed nationally in 2023 — a national record — at 77.4 per million population; first year exceeding 600 unrelated-donor transplants
    • REDMO registry: 492,958 registered donors (WMDA certified March 2024); access to 101 international registries and 40+ million global donors; median donor search time 28 days with 93% match success within two months
    • Cord blood bank: 62,097 units stored — Europe's largest, second globally after United States; 7.4% of worldwide supply
    • Hospital Clínic de Barcelona survival outcomes: 70% one-year and 55% five-year overall survival for allogeneic transplantation; 100% one-year and 85% five-year survival for autologous transplantation
    • Haploidentical transplants available at 16+ Spanish centres contributing to GETH-TC registries with 1,454+ enrolled patients since 2012
    • Multilingual international patient services at barnaclínic+ and Clínica Universidad de Navarra with treatment planning, accommodation coordination, and extended care programs; day hospital access 7 days/week
    • Active EBMT benchmarking participation; GETH-TC publishes multi-centre studies in leading haematology journals; Spain contributed to 2023 EBMT report on HCT and hosted sixth European CAR-T meeting in 2024

    Read the full Spain report →

  4. 4 Jordan JO 4.5/5 Good Jordan operates a single FACT-JACIE accredited transplant center (KHCC) with excellent outcomes exceeding Score 4 benchmarks across all major dimensions: 70–85% five-year survival rates, very low treatment-related mor... Full report
    The evidence behind this score 5 cited points
    • KHCC holds FACT-JACIE accreditation for Hematopoietic Cellular Therapy and JCI disease-specific cancer certification; approximately 200 transplants annually with >85% success rate (2022)
    • Published 5-year survival rates of 70% (2003–2009) improved to >85% (2022); day-100 treatment-related mortality of 4.8% for Hodgkin's lymphoma autologous transplant and 3% for thalassemia exceed international benchmarks
    • All transplant modalities available: autologous, allogeneic (matched related/unrelated), haploidentical, and cord blood; HEPA-filtered isolation rooms and advanced cell processing laboratory (CTAG) provide specialized infrastructure
    • Comprehensive international patient services: dedicated Office of International Patient Affairs with visa coordination, medical translation, financial estimation, and personal coordinator; EBMT registry participation for international outcome benchmarking
    • Concentration of transplant capacity at single KHCC center (87% of national volume 2003–2017) and absence of domestic bone marrow donor registry present as programmatic gaps despite robust international registry access

    Read the full Jordan report →

  5. 5 Israel IL 4.5/5 Good Israel operates one of the world's most sophisticated stem cell transplant systems with the highest allogeneic HCT rate globally (441 per 10 million), multiple JACIE/FACT-accredited centers performing 500-600+ transpl... Full report
    The evidence behind this score 5 cited points
    • Hadassah achieved full JACIE accreditation (2018); Sheba holds JACIE for HPC collection + FACT/NETCORD and AABB certifications; Schneider Children's JACIE-accredited; all major centers JCI-accredited
    • Israel records world's highest allogeneic HCT rate of 441 per 10 million inhabitants and highest CAR-T rate of 231 per 10 million per EBMT 2022-2023 data
    • Reported survival rates of 85-90% for leukemia at major centers; 93% overall survival for SCID patients identified via newborn screening at Sheba
    • Ezer Mizion registry contains 1.28+ million donors with WMDA accreditation and NMDP affiliation providing access to 40+ million global donors; 6,544 transplants facilitated in 50 countries
    • Sheba Medical Center operates as Europe's largest CAR-T center with point-of-care manufacturing in 10-11 days; Sheba holds global patient services with 8-language support and institutional recognition as 8th-ranked hospital globally by Newsweek in 2024

    Read the full Israel report →

  6. 6 Singapore SG 4.5/5 Good Singapore demonstrates world-class stem cell transplantation capabilities with multiple FACT/JACIE-accredited centers (NCIS, SGH, NUH, KKH) and exceptional clinical outcomes. Paediatric allogeneic HSCT outcomes are ou... Full report
    The evidence behind this score 5 cited points
    • Multiple internationally accredited centers: NCIS is the only HSCT programme in Asia with FACT accreditation; SGH holds FACT-JACIE (2016); NUH Paediatric achieved FACT (2012); Singapore Cord Blood Bank is FACT-NetCord certified; four private hospitals hold JCI accreditation
    • Exceptional outcome statistics: KKH paediatric allogeneic HSCT (2019–2023) showed 1-year OS of 90.4% with 1-year TRM of 3.3%; national HSCT mortality during COVID-19 remained below 10% versus 19% internationally
    • Comprehensive donor registry and modalities: BMDP links to 30+ million donors through 90+ WMDA registries; all transplant types available including haploidentical (Haplo-2017 protocol) and cord blood; SGH performs 80–100 transplants annually
    • Established international patient infrastructure: JCI-accredited private hospitals provide airport transfer, language interpretation, visa assistance, accommodation arrangement; NCIS maintains dedicated international patient pathway; CFCH operates with transparent cost structures
    • Published outcomes and international benchmarking: Singapore is APBMT registry member, hosted 29th APBMT Congress 2024; outcomes published in peer-reviewed journals and compared to international benchmarks; SGH explicitly states outcomes comparable to major global centres

    Read the full Singapore report →

  7. 7 Hungary HU 4.0/5 Good Hungary operates at least one major FACT/JACIE-accredited transplant center (University of Debrecen) performing 101+ annual procedures with 5-year survival rates of 86% for Hodgkin lymphoma and 71.4% for pediatric AML... Full report
    The evidence behind this score 6 cited points
    • University of Debrecen Division of Haematology holds JACIE accreditation; MEDYAG Kft. (Debrecen) received JACIE accreditation in 2024
    • 5-year overall survival of 86% for autologous SCT in Hodgkin lymphoma (n=126, 2016–2020 multicenter study) and 71.4% two-year OS for pediatric AML, exceeding Score 4 survival thresholds
    • Documented annual transplant volume of 101 procedures at Debrecen in 2017 with target capacity of 150/year post-expansion; national volume approximately 400 procedures annually
    • WMDA member since 1992 with EMDIS-connected online access to approximately 40 million international donors; all five transplant modalities available including haploidentical and cord blood programs
    • International patient services established at major centers (Semmelweis International Patient Office, Debrecen coordination, Déméter House with 14 family apartments for pediatric patients), though adult-specific dedicated housing and coordinator roles are limited
    • Active participation in EBMT registry for European-level benchmarking; University of Debrecen membership in EuroBloodNet for rare hematological diseases

    Read the full Hungary report →

  8. 8 Turkey TR 4.0/5 Good Turkey demonstrates good stem cell transplant quality with multiple major centers performing over 250 transplants annually and achieving 70-90% success rates for standard cases. The country has established accredited ... Full report
    The evidence behind this score 3 cited points
    • Over 250 annual transplants at leading centers with 70-90% success rates for matched-related donor procedures, demonstrating high volume and strong outcomes comparable to international standards
    • TURKOK registry with 600,000 WMDA-registered donors established 2015 and participation in EMDIS international network, enabling 92-day average donor search compared to 176 days for German registry
    • Comprehensive international patient infrastructure with 24/7 international patient centers, all-inclusive packages (€45,000-€65,000), dedicated accommodation and translator support, plus specialized transplant modalities (autologous, allogeneic, haploidentical, CAR-T)

    Read the full Turkey report →

  9. 9 Japan JP 4.0/5 Good Japan operates one of the world's largest stem cell transplant programs with 267 certified centers, exceptional donor registry outcomes (96% 8/8 HLA match rate), and world-leading cord blood transplantation (>30% of g... Full report
    The evidence behind this score 5 cited points
    • 267 JSTCT-certified HCT centers (189 adult, 78 pediatric) performing 5,500+ annual transplants with rigorous national certification and mandatory TRUMP registry oversight
    • JMDP donor registry: 547,708 donors with 96% 8/8 HLA match probability and ~122 day search-to-transplant timeline; Japan accounts for >30% of global cord blood transplants via 11 public banks
    • Five-year net survival rates: lymphoid malignancies 57.3%, cord blood 100-day survival 78.9%, with improving trends; younger patients (15-44) achieving 72.3% for myeloid malignancies
    • Government-supported Visa for Medical Stay (up to 6 months renewable), interpreter services at major centers, and 25 JCI-accredited hospitals in Japan
    • International collaboration: JSTCT/JDCHCT integrated with CIBMTR and EBMT for outcome benchmarking; access to novel therapies including ruxolitinib and ibrutinib with published Japanese cohort data

    Read the full Japan report →

  10. 10 United Kingdom GB 4.0/5 Good The United Kingdom maintains multiple JACIE-accredited transplant centers with exceptional volume (Royal Marsden and King's College Hospital each performing 200+ annual transplants) and access to sophisticated donor r... Full report
    The evidence behind this score 5 cited points
    • 14+ JACIE-accredited centers achieved or renewed accreditation in 2024; Royal Marsden >200 annual transplants, King's College Hospital ~200/year, GOSH ~90-100/year
    • Adult 5-year overall survival approximately 50%; paediatric 1-year allograft survival 82-94% at GOSH; high-volume centers demonstrate superior outcomes for standard-risk populations
    • UK Registry 2.37 million donors; global access to 40+ million through WMDA; NHS Cord Blood Bank 20,000 units (4th largest globally); haploidentical and cord blood programs available
    • GOSH Harris International Patients Centre with Dubai liaison office; established international patient services and private cost documentation (£150,000-£200,000)
    • All transplant modalities available including CAR-T therapy; regular outcome reporting to EBMT international registry and BSBMTCT database

    Read the full United Kingdom report →

  11. 11 United Arab Emirates AE 3.5/5 Moderate The UAE has achieved exceptional outcomes through a FACT-accredited flagship center (ADSCC) with 97% one-year survival for autologous transplants and 100% for pediatric matched-related donors, supported by strong regu... Full report
    The evidence behind this score 7 cited points
    • FACT accreditation (April 2024) — first in UAE, second in Middle East; AABB accreditation (2025); JCI Gold Seal and DoH Centre of Excellence designation
    • Autologous HSCT: 97% one-year overall survival with 100% engraftment in 48 adult patients; pediatric matched related donor: 100% overall survival and 0% transplant-related mortality in 25 consecutive cases
    • Individual ADSCC and Burjeel annual volumes estimated at 25-40 transplants per center (below Score 4 threshold of >50), with cumulative UAE program ~260 transplants since 2020
    • Allogeneic 100-day treatment-related mortality of 33% in small early cohort (n=9), significantly above international benchmark of 10-15%
    • Emirates Bone Marrow Donor Registry exists but historically small with under-representation of Arab donors; no documented average search time for unrelated donor matching
    • Haploidentical transplant programs not formally documented in public literature, limiting donor options for patients without sibling matches
    • No formally integrated accommodation arrangements for 3–6 month international patient stays; dedicated international coordinators present but housing must be arranged independently

    Read the full United Arab Emirates report →

  12. 12 South Korea KR 3.5/5 Moderate South Korea demonstrates strong stem cell transplant infrastructure with competitive clinical outcomes and comprehensive international patient services, but is limited by the absence of FACT/JACIE accreditation. Treat... Full report
    The evidence behind this score 6 cited points
    • 38 HSCT centers across South Korea with Seoul National University performing >3,500 cases as of 2024 and Asan Medical Center performing 3,700 combined autologous and allogeneic transplants (1993-2016)
    • Treatment-related mortality rates of 2.9% at 50 days and 8.3% at 100 days, demonstrating excellent outcomes compared to international standards (Score 5 threshold: <10%)
    • No FACT or JACIE accredited transplant centers identified; accreditation exists only for general hospital quality (JCI), not transplant-specific standards
    • Comprehensive international patient services including multilingual staff (English, Chinese, Mongolian, Russian, Japanese, Arabic), dedicated International Healthcare Centers at major hospitals, and over 20,086 international patients annually visiting Asan Medical Center
    • Access to international donor registries with 42 million potential donors globally through partnerships; domestically, 28% of Korean patients find matched donors through KMDP with additional access to Japanese registry (JMDP) for 30% of patients without domestic matches
    • All major transplant modalities available including haploidentical, cord blood, and alternative donor programs; centers actively offering CAR-T cell therapy since 2022

    Read the full South Korea report →

  13. 13 Mexico MX 3.5/5 Moderate Mexico demonstrates exceptional clinical outcomes with 100-day treatment-related mortality rates of 1.9% for autologous and 6.1% for allogeneic transplants—exceeding Score 5 thresholds—and survival rates of 61% (autol... Full report
    The evidence behind this score 7 cited points
    • 100-day treatment-related mortality of 1.9% for autologous and 6.1% for allogeneic HSCT—better than Score 5's <10% threshold [Outcomes of HSCT in Mexico - Leon Rodriguez et al. - 2017]
    • Ten-year overall survival rates of 61% for autologous and 57% for allogeneic HSCT within 60-70% range for Score 4 [Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran - 2017]
    • Approximately 118 annual transplants across four major public centers (2015-2018), exceeding 50-transplant threshold for Score 4 [Outcomes of HSCT in Mexico - Leon Rodriguez et al. - 2017]
    • At least one FACT-accredited center in Monterrey, but no documented JACIE accreditation; falls short of Score 5's 'multiple' centers [FACT Accredited Institutions - 2024]
    • Infrastructure for international patients 'markedly underdeveloped' with no dedicated long-term housing and no documented international patient coordinators [Research Report Analysis]
    • Underdeveloped domestic bone marrow donor registry (DONORMO/UCBB); must rely on international registries like NMDP/Be The Match for unrelated donor searches [Outcomes of HSCT in Mexico - Leon Rodriguez et al. - 2017]
    • Haploidentical programs established with 64.1% 60-month overall survival at Centro Médico ABC, comparable to high-income countries [Outcomes of Haploidentical SCT for ALL Mexico - Carrillo Jurado et al. - 2025]

    Read the full Mexico report →

  14. 14 Malaysia MY 3.5/5 Moderate Malaysia operates well-established stem cell transplant programs with approximately 400 annual procedures and 60-70% overall survival rates, exceeding Score 3 thresholds. However, the complete absence of FACT or JACIE... Full report
    The evidence behind this score 8 cited points
    • No FACT or JACIE accreditation at any Malaysian center; only JCI (hospital-wide) accreditation at private hospitals
    • 60-70% overall survival rates (2010-2015 cohort); 63% 10-year OS for AML allogeneic patients (1987-2010)
    • Approximately 400 annual transplants nationally; Hospital Ampang performs ~200/year, exceeding major center thresholds
    • Only 3% of allogeneic transplants use matched unrelated donors; MSCR has 31,200 donors vs. international registries with millions
    • Treatment-related mortality not systematically reported or disclosed publicly
    • No annual published outcome reports or international benchmarking; peer-reviewed data is historical (pre-2015)
    • Dedicated International Patient Centres at JCI-accredited hospitals with multilingual coordinators and telemedicine follow-up
    • 13 transplant centers with access to haploidentical, cord blood, and autologous modalities

    Read the full Malaysia report →

  15. 15 Poland PL 3.5/5 Moderate Poland operates a substantial HSCT system with approximately 2,057 annual procedures across 20 centers, a world-leading unrelated donor registry (2.47M typed donors), and access to all advanced transplant modalities i... Full report
    The evidence behind this score 6 cited points
    • 2,057 total HSCTs in 2024 (1,191 autologous + 866 allogeneic) across 20 Ministry of Health-authorized centers; University Children's Hospital Krakow holds JACIE accreditation (2024) for pediatric program; no confirmed JACIE certification for major adult centers
    • 3-year overall survival rates from PALG multicenter study: 73.6% (PTCy-MMUD), 49.1% (PTCy-haploidentical), 33.4% (ATG-MMUD); treatment-related mortality not publicly consolidated
    • Donor registry of 2.47M Polish donors (DKMS Fundacja + Poltransplant) represents one of world's largest national pools with 92%+ HLA intermediate-to-high resolution typing; access to 44M global donors via WMDA
    • All transplant modalities available: autologous, allogeneic related/unrelated, haploidentical (94 in 2024), cord blood (PBKM EBMT member), and commercial CAR-T (5 certified centers since 2022)
    • International patient infrastructure underdeveloped: no nationally coordinated medical tourism pathways, no dedicated international patient coordinators at major public centers, no purpose-built accommodation for 3-6 month post-transplant stays; costs $20,000-$60,000 (60-80% below Western Europe)
    • Active research culture with PALG/Polish Myeloma Group publications in peer-reviewed journals, EBMT registry participation, and Wrocław HLA proficiency testing serving 67 labs in 16 countries; no center-level outcome benchmarking published for international comparison

    Read the full Poland report →

  16. 16 Brazil BR 3.5/5 Moderate Brazil operates a mature, nationally coordinated stem cell transplant program with four FACT-JACIE accredited institutions performing approximately 3,991 annual procedures with regular outcome reporting to internation... Full report
    The evidence behind this score 5 cited points
    • Four FACT-JACIE Hematopoietic Cellular Therapy–accredited institutions with 3,991 annual transplants (1,462 allogeneic, 2,529 autologous)
    • Autologous 2-year overall survival 82% with non-relapse mortality 8%; allogeneic 2-year overall survival 59.8% with non-relapse mortality 21.6% across 11,210 patients (2012–2023)
    • REDOME donor registry is world's 3rd largest with approximately 4–5 million registered donors; haploidentical and cord blood programs available
    • Hospital Israelita Albert Einstein International Patient Center with JCI accreditation, FACT-JACIE certification since 2012, and over 1,300 completed transplants; CHN Niterói performs ~130 annual transplants with 26 HEPA-filtered isolation rooms
    • Regular outcome reporting to CIBMTR with outcomes explicitly described as comparable to US registry data; ANVISA regulatory oversight (RDC 214) and Ministry of Health SIPAC accreditation system in place

    Read the full Brazil report →

  17. 17 Thailand TH 3.5/5 Moderate Thailand demonstrates strong clinical outcomes comparable to Western standards (92% one-year survival at Samitivej, 0% 100-day TRM for pediatric thalassemia haploidentical transplants) and maintains four established t... Full report
    The evidence behind this score 9 cited points
    • Four active transplant centers (Siriraj, Ramathibodi, Chulalongkorn, Pramongkutklao) with 120-150 total annual transplants (approximately 30-37 per center)
    • Samitivej reports 92% one-year survival for bone marrow transplantation, exceeding European benchmarks of ≥88%
    • 0% 100-day transplant-related mortality for pediatric thalassemia haploidentical transplants, compared to European benchmark of ≤4%
    • No Thai centers appear in FACT or JACIE accredited databases - only JCI general hospital accreditation available
    • Full access to international donor registries with over 30 million potential donors worldwide through WMDA membership
    • Haploidentical programs reduce donor matching requirements to 50%, with family members serving as donors
    • Comprehensive international patient services at major hospitals with multilingual support, accommodation coordination, and telemedicine follow-up
    • High chronic GVHD rates noted, especially in peripheral blood stem cell transplant recipients
    • No national outcome registry or systematic benchmarking against international standards

    Read the full Thailand report →

  18. 18 India IN 3.5/5 Moderate India demonstrates substantial stem cell transplantation capacity with 114 centers and comparable survival rates (60-90%), meeting several Score 4 criteria. However, limited international accreditation (only 1 FACT-ac... Full report
    The evidence behind this score 7 cited points
    • Only 1 FACT-accredited transplant center identified in Gujarat versus multiple needed for Score 5
    • Survival rates of 60-90% with major hospitals reporting 90%+ success rates, comparable to international standards
    • Day-100 non-relapse mortality of 18% in recent haploidentical cases, exceeding Score 4 threshold of 10-15%
    • DATRI registry with 657,361 donors but only 15% of patients finding domestic matches; international registry access through partnerships
    • 2,533 transplants in 2019 across 114 centers (~20-28 per center average), though major centers exceed 100+ annual volume
    • Comprehensive international patient services with dedicated Guest Relation Officers, accommodation support, and 3-month follow-up programs
    • Regulatory framework incomplete: recommended methods and release criteria for graft manipulation still not available in India

    Read the full India report →

  19. 19 Colombia CO 3.0/5 Moderate Colombia operates established stem cell transplant programs at 13 authorized centers with adequate infrastructure and all major transplant modalities available. National success rates of 62% and treatment-related mort... Full report
    The evidence behind this score 5 cited points
    • No Colombian transplant center holds FACT or JACIE accreditation; Fundación Valle del Lili holds JCI and EFI laboratory accreditation but not international transplant center credentials.
    • National aggregate success rate of 62% for first hematopoietic progenitor cell transplants; Fundación Valle del Lili reports 87% at 1 year and 81% at 5 years for haploidentical transplants in inborn errors of immunity.
    • Infection-related mortality accounts for 45% of treatment-related deaths (versus 5–11% internationally), with 68.1% of PICU admissions post-transplant driven by infection and 55.8% of organisms showing antimicrobial resistance.
    • Instituto de Cancerología Las Américas performs ~140 transplants annually; Clínica de Marly has completed 3,000+ procedures over 30+ years; limited domestic donor registry of only 4,435 HLA-typed donors with 97.4% Mestizo composition.
    • Bilingual international patient coordinators, virtual pre-consultation, and remote follow-up available at major centers; cost savings of 60–70% versus US; however, no dedicated transplant housing and Level 3 US travel advisory noted.

    Read the full Colombia report →

Reading the field

What separates a good programme from a dangerous one

Every country above is graded against this published scale — the same 1–5 rubric for stem cell transplant quality, top to bottom. How we score →

  1. 5/5 Excellent

    Multiple FACT/JACIE accredited centers with >100 annual transplants each, published 5-year survival rates >70% for standard risk patients, treatment-related mortality <10%, access to international donor registries with <30 day average search time, comprehensive international patient programs with dedicated housing and coordinators, haploidentical and cord blood programs available, outcomes published and benchmarked internationally.

  2. 4/5 Good

    At least one major FACT/JACIE accredited center performing >50 annual transplants, survival rates 60-70%, treatment-related mortality 10-15%, good donor registry access, established international patient services, most transplant modalities available, regular outcome reporting to international databases.

  3. 3/5 Moderate

    Transplant programs at major medical centers with 20-50 annual procedures, survival rates 50-60%, treatment-related mortality 15-20%, limited donor registry access, basic international patient accommodation, autologous and some allogeneic programs, inconsistent outcome reporting.

  4. 2/5 Poor

    Few transplant centers with <20 annual procedures, survival rates 40-50%, high treatment-related mortality >20%, minimal donor matching capabilities, limited support for international patients, primarily autologous transplants only, poor outcome transparency.

  5. 1/5 Very Poor / Unavailable

    No established stem cell transplant programs, or programs with very poor outcomes (survival <40%), no international accreditation, no donor registry access, no accommodation for international patients requiring extended stays, lack of specialized transplant infrastructure.

The reports

The full country reports under this lens

Each destination we have assessed has a full, cited report — the detailed analysis behind its score. The verdict is free; the report is the depth.

Clinics & providers

The clinics our research names

Named hospitals, clinics and centres cited across these findings — each carrying the specialties our reports record. Follow one to the reports behind it.

References

The sources behind these assessments

The distinct sources cited across these published reports — every finding carries its own citations; this is the union, each linking back to the reports that lean on it.

  1. Untitled source www.jdchct.or.jp/en/data/slide/2023 Cited in Stem Cell Transplant Quality in Japan
  2. Untitled source www.mdrindia.org Cited in Stem Cell Transplant Quality in India
  3. Untitled source www.scienceasia.org/2007.33(s1 Cited in Stem Cell Transplant Quality in Thailand
  4. Untitled source adscc.ae/who-we-are Cited in Stem Cell Transplant Quality in United Arab Emirates
  5. Untitled source alttreatment.io/2025/08/19/does-turkey-have-stem-cell-therapy-in-2025 Cited in Stem Cell Transplant Quality in Turkey
  6. Untitled source ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e23306 Cited in Stem Cell Transplant Quality in United States
  7. Untitled source ashpublications.org/bloodadvances/article/4/24/6283/474704/How-much-has-allogeneic-stem-cell-transplant Cited in Stem Cell Transplant Quality in United States
  8. Untitled source asjo.in/haploidentical-stem-cell-transplant-established-treatment-expanding-horizons Cited in Stem Cell Transplant Quality in India
  9. Untitled source auragens.com/is-stem-cell-therapy-expensive-get-the-facts-before-deciding Cited in Stem Cell Transplant Quality in United States
  10. Untitled source bct.apbmt.org/articles/bct-2022-002 Cited in Stem Cell Transplant Quality in Thailand
  11. Untitled source beikecelltherapy.com/stem-cell-treatment-cost-quality-comparisons Cited in Stem Cell Transplant Quality in United States
  12. Untitled source bloodstemcell.hrsa.gov/about/legislation Cited in Stem Cell Transplant Quality in United States
  13. Untitled source bloodstemcell.hrsa.gov/data/about-data/participating-transplant-centers Cited in Stem Cell Transplant Quality in United States
  14. Untitled source bloodstemcell.hrsa.gov/data/donation-and-transplantation-statistics Cited in Stem Cell Transplant Quality in India, Stem Cell Transplant Quality in United States
  15. Untitled source bloodstemcell.hrsa.gov/data/donation-and-transplantation-statistics/transplant-activity-report Cited in Stem Cell Transplant Quality in India, Stem Cell Transplant Quality in Turkey, Stem Cell Transplant Quality in United States
  16. Untitled source bloodstemcell.hrsa.gov/sites/default/files/bloodstemcell/about/legislation/2019cwbillyoungreporttocongress.pdf Cited in Stem Cell Transplant Quality in United States
  17. Untitled source bmdp.org/international-registry Cited in Stem Cell Transplant Quality in Thailand
  18. Untitled source bmt.confex.com/tandem/2015/webprogram/Paper5949.html Cited in Stem Cell Transplant Quality in India
  19. Untitled source cancer.uams.edu/stem-cell-transplant Cited in Stem Cell Transplant Quality in United States
  20. Untitled source cells4life.com/us/2024/09/what-are-haplo-cord-blood-transplants Cited in Stem Cell Transplant Quality in United States
  21. Untitled source cibmtr.org/CIBMTR/Data-Operations/Center-Membership/SCTOD-Requirements Cited in Stem Cell Transplant Quality in United States
  22. Untitled source cibmtr.org/CIBMTR/Resources/Summary-Slides-Reports Cited in Stem Cell Transplant Quality in United States
  23. Untitled source cibmtr.org/CIBMTR/Utility-Nav/Patients/Study-Summaries Cited in Stem Cell Transplant Quality in United States
  24. Untitled source datri.org Cited in Stem Cell Transplant Quality in India

Explore the source archive →

In plain language

Start exploring the knowledge base

The field's shorthand our reports use, sized by how often it comes up. Follow any term to its full entry and the reports that use it.

For readers weighing this decision

Ways to read the evidence

The verdict is always free. A membership opens the full analysis and every cited source — this specialty, the whole library, or everything for good.

  • One specialty · annual

    Therapeutic Interventions

    $49.00 / year

    $49.00/year

    Every report in this specialty — full analysis and every cited source — as each is published.

    Take this specialty

  • Full library · annual

    The whole library

    $199.00 / year

    $199.00/year

    The complete evidence behind every finding in every specialty, while your decision is live.

    Take the full library
  • Most readers

    Lifetime · one payment

    Everything, for good

    $499.00 once

    $499.00 (one-time)

    Every finding we publish today and hereafter — no renewal, no expiry. The tier we point most readers to.

    Take lifetime access

Prefer to pay per report? A single report is $29.00, yours to keep — browse the reports. The verdict is always free.

Where to go from here · Stem Cell Transplant Quality

no scope is a dead end — step up to the specialty, drill into a factor, or pivot across to a country or a comparison